RARX News and Press, Ra Pharmaceuticals Inc. From 04/01/19

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that data from its Phase 2 clinical trial of zilucoplan for the treatment of generalized myasthenia gravis (gMG) have been selected for an Emerging Science dual oral and poster presentation at the 2019 American Academy of Neurology (AAN)...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his 2% trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts. Winning Bounce/Lag Momentum Stocks...

(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model and comments are expressly based on his own proprietary methodology and forecasts. Winning Bounce/Lag Momentum Stocks for Week 12 of 2019 The Bounce/L...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model and comments are expressly based on his own proprietary methodology and forecasts. Winning Bounce/Lag Momentum Stocks For Week 11 of 2019 The Bounce/La...

Ra Pharmaceuticals (NASDAQ: RARX ): Q4 GAAP EPS of -$0.47 beats by $0.04 . More news on: Ra Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more ...

Successful completion of Phase 2 trial of zilucoplan in generalized myasthenia gravis (gMG) with rapid, clinically meaningful, and statistically significant reductions in QMG and MG-ADL Zilucoplan extended release (XR) achieves greater than one week of target drug concentrations in non...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that Doug Treco, Ph.D., President and Chief Executive Officer of Ra Pharma, will present at the Cowen 39 th Annual Health Care Conference on Monday, March 11, 2019 at 1:30 p.m. E.T. The conference is being held at Boston Marriott Copley...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today joins forces with 30 million healthcare advocates around the world for the 12th Annual Rare Disease Day ® , an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people l...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that Ramin Farzaneh-Far, M.D., Chief Medical Officer of Ra Pharma, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 2:30 p.m. E.T. The conference is being held at the Lotte New Yor...